Vital Sign MonitoringNCT03356184
Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients
A study testing The Rhea Vital Sign Vigilance Device Group and The Earlysense System Device Group in people with Vital Sign Monitoring, run by Darma Inc. at 1 site in United States.
Trial summary
This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring. The primary variables for the analysis of heart rate (HR) and respiratory rate (RR) are each of the overall mean roots mean square difference… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Vital Sign Monitoring
- What is being tested?
- The Rhea Vital Sign Vigilance Device Group and The Earlysense System Device Group
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteUnited States
- Study dates
- 11 May 2018to 15 May 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Male or female, 18 years old and above.
- Provide written informed consent.
- Weight ranging from 20 to 150 kg inclusive.
- Are located in a non-ICU hospital setting.
- Agree to not eat during the testing period.
- Agree to keep still.
Who cannot join
- Are connected to a device which may interfere with the device monitoring in this study.
- Are receiving any bedside care which may be incompatible with the study procedures.
- Sleep apnea.
- Pregnant or breast feeding.
- A likely need to receive or undergo a procedure during the testing period.
- Cannot accept a nasal cannula, or have a monitor lead placed on the chest.
- A significant medical condition in the judgement of the investigator, which may compromise the study testing procedures.
- Are wearing pacemaker or defibrillator.
Trial locations and contacts
1 site in 1 country.
United States1 site
Virginia Commonwealth University School of Medicine
Richmond, Virginia, 23298-0102
About this study
This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring. The primary variables for the analysis of heart rate (HR) and respiratory rate (RR) are each of the overall mean roots mean square difference (RMSD). Results of the investigational device and reference device compared with the patient monitor is evaluated to see if there are equivalent. Motion and bed exit accuracy will be evaluated by comparing with the manual observation.
Read the detailed description
Tests (periods 1 and 2), one of the contact-free devices will be used to monitor the HR and RR, while being compared with the Patient Monitor. The RHEA investigational device and reference device will be used to monitor the same subject at different times, as the sensors of the two devices are placed at a similar location of the bed. HR and RR will be recorded for all three devices.
The primary hypotheses for HR, are as follows:
Adults HO: μ = 3.25 vs. HA: μ < 3.25
The primary hypotheses for RR, are as follows:
Adults HO: μ = 2.25 vs. HA: μ < 2.25 where μ represents the population mean HR or RR. If the upper bound of the confidence interval is less than the hypothesized value, the corresponding null hypothesis will be rejected. Comparison of the performance of the two contract-free devices will be performed on the recorded results via statistical analysis. The hypothesis here is that the two devices have equivalent performance. The third test will assess the ability of the RHEA device to accurately detect motion in or exit from the bed, as compared to the manual observation. Motion and no motion accuracy will each be calculated along with their respective two-sided 95% confidence intervals.
- Conditions
- Vital Sign Monitoring
- Being tested
- The Rhea Vital Sign Vigilance Device Group, The Earlysense System Device Group
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The Rhea Vital Sign Vigilance Device GroupDevice
The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
The Earlysense System Device GroupDevice
The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
| Study group | Role | What they receive |
|---|---|---|
| The Rhea Vital Sign Vigilance Device Group | Experimental | The RHEA device and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants. Receives: Device: The Rhea Vital Sign Vigilance Device Group |
| The Earlysense System Device Group | Active comparator | The reference device -EarlySense System and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants. Receives: Device: The Earlysense System Device Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Root-mean-square Deviation of Heart Rate
Calculate the root-mean-square deviation (RMSD) of the heart rate using 20 pairs of valid and synchronously recorded heart rate of investigational device and patient monitor.
Measured: 30 days
Root-mean-square Deviation of Respiratory Rate
Calculate the root-mean-square deviation (RMSD) of the respiratory rate using 20 pairs of valid and synchronously recorded respiratory rate of investigational device and patient monitor.
Measured: 30 days
Secondary outcomes (4)
Heart Rate t Test Comparison result between the Investigational Device and the Reference Device
Record 20 valid heart rate displayed in the reference device and patient monitor at the same time every one minute.
Calculate the t test results for heart rate for the reference device and the investigational device.
Measured: 30 days
Respiratory Rate t Test Comparison result between the Investigational Device and the Reference Device
Record 20 valid respiratory rate displayed in the reference device and patient monitor at the same time every one minute. Calculate the t test results for respiratory rate for the reference device and the investigational device.
Measured: 30 days
Motion Notification Accuracy(%)
Record the time for each instructed movements from manual observation and time for movements notification shown in the investigational device. Calculate the times matched between these two to get the accuracy.
Measured: 30 days
Bed Exit Notification Accuracy(%)
Record the time for each instructed bed exit from manual observation and time for bed exit notification shown in the investigational device. Calculate the times matched between these two to get the accuracy.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2017
- Study start11 May 2018
- Primary completion15 May 2018
- Study completion15 May 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vital Sign MonitoringStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Model description
- The RHEA device and Patient Monitor are used to monitor the heart rate (HR) and respiratory rate (RR) of participants at the same time in Test 1. The reference device and patient monitor are used to monitor the heart rate and respiratory rate of the same participant at the same time in Test 2. The two tests results will be compared and evaluated the accuracy of the two devices. And the RHEA device is used alone to evaluate the accuracy of motion and no motion.
- Masking
- None (open label)
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Darma Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Virginia Commonwealth University
- Responsible party
- Sponsor
- Investigators
- Ava Puccio, RN, Principal investigator, University of Pittsburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03356184
- Sponsor's protocol ID
- RHEA EL30-2017-006
- Status last verified
- Apr 2019
- First submitted
- 13 Nov 2017
- Last updated
- 16 Apr 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients
- ClinicalTrials.gov ID
- NCT03356184
- Acronym / sponsor ID
- RHEA EL30-2017-006
- Conditions
- Vital Sign Monitoring
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Darma Inc.Industry (pharma, biotech, devices)
- Collaborators
- Virginia Commonwealth University
- Study start
- 11 May 2018 (actual)
- Primary completion
- 15 May 2018 (actual)
- Study completion
- 15 May 2018 (actual)
- First posted
- 29 Nov 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring. The primary variables for the analysis of heart rate (HR) and respiratory rate (RR) are each of the overall mean roots mean square difference (RMSD). Results of the investigational device and reference device compared with the patient monitor is evaluated to see if there are equivalent. Motion and bed exit accuracy will be evaluated by comparing with the manual observation.
Detailed description
Tests (periods 1 and 2), one of the contact-free devices will be used to monitor the HR and RR, while being compared with the Patient Monitor. The RHEA investigational device and reference device will be used to monitor the same subject at different times, as the sensors of the two devices are placed at a similar location of the bed. HR and RR will be recorded for all three devices.
The primary hypotheses for HR, are as follows:
Adults HO: μ = 3.25 vs. HA: μ < 3.25
The primary hypotheses for RR, are as follows:
Adults HO: μ = 2.25 vs. HA: μ < 2.25 where μ represents the population mean HR or RR. If the upper bound of the confidence interval is less than the hypothesized value, the corresponding null hypothesis will be rejected. Comparison of the performance of the two contract-free devices will be performed on the recorded results via statistical analysis. The hypothesis here is that the two devices have equivalent performance. The third test will assess the ability of the RHEA device to accurately detect motion in or exit from the bed, as compared to the manual observation. Motion and no motion accuracy will each be calculated along with their respective two-sided 95% confidence intervals.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The RHEA device and Patient Monitor are used to monitor the heart rate (HR) and respiratory rate (RR) of participants at the same time in Test 1. The reference device and patient monitor are used to monitor the heart rate and respiratory rate of the same participant at the same time in Test 2. The two tests results will be compared and evaluated the accuracy of the two devices. And the RHEA device is used alone to evaluate the accuracy of motion and no motion.
| Arm | Type | Receives |
|---|---|---|
| The Rhea Vital Sign Vigilance Device Group | Experimental | Device: The Rhea Vital Sign Vigilance Device GroupThe RHEA device and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants. |
| The Earlysense System Device Group | Active comparator | Device: The Earlysense System Device GroupThe reference device -EarlySense System and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Male or female, 18 years old and above.
- Provide written informed consent.
- Weight ranging from 20 to 150 kg inclusive.
- Are located in a non-ICU hospital setting.
- Agree to not eat during the testing period.
Key exclusion criteria (8 listed)
- Are connected to a device which may interfere with the device monitoring in this study.
- Are receiving any bedside care which may be incompatible with the study procedures.
- Sleep apnea.
- Pregnant or breast feeding.
- A likely need to receive or undergo a procedure during the testing period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The Rhea Vital Sign Vigilance Device GroupThe RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants. | Device | The Rhea Vital Sign Vigilance Device Group |
| The Earlysense System Device GroupThe reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants. | Device | The Earlysense System Device Group |
Primary outcome
Root-mean-square Deviation of Heart Rate
Time frame: 30 days
Calculate the root-mean-square deviation (RMSD) of the heart rate using 20 pairs of valid and synchronously recorded heart rate of investigational device and patient monitor.
Root-mean-square Deviation of Respiratory Rate
Time frame: 30 days
Calculate the root-mean-square deviation (RMSD) of the respiratory rate using 20 pairs of valid and synchronously recorded respiratory rate of investigational device and patient monitor.
4 secondary outcomes
Heart Rate t Test Comparison result between the Investigational Device and the Reference Device
Time frame: 30 days
Respiratory Rate t Test Comparison result between the Investigational Device and the Reference Device
Time frame: 30 days
Motion Notification Accuracy(%)
Time frame: 30 days
Bed Exit Notification Accuracy(%)
Time frame: 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2019.
- Individual participant dataSharing planned: No
Related trials for Vital Sign Monitoring
Recruiting
Hospital Based Continuous Patient Monitoring System
Trauma, Appendectomy
Not yet recruitingObservational study
ADVANCE-FORSEE. ADVANCEd Video Monitoring FOR Early Signaling of Adverse Events and Optimal dischargE Planning.
Vital Signs Monitoring, Complication
RecruitingObservational study
Vision Baby : The Measurement of Vital Signs in Neonates by Lifelight® Software in Comparison to the Standard of Care
Neonatal Diseases and Abnormalities, Vital Sign Monitoring
Recruiting
The Effect of Diaphragmatic Breathing Exercises Before Gastroscopy on Anxiety, Fear, and Vital Signs
Breath Exercise, State Anxiety
Recruiting
Continuous Versus Intermittent Ward Monitoring
Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ava Puccio, RN principal investigator
University of Pittsburgh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing The Rhea Vital Sign Vigilance Device Group and The Earlysense System Device Group in people with Vital Sign Monitoring, run by Darma Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Root-mean-square Deviation of Heart Rate (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2019.